Abstract 1896P
Background
Management of cancer patients at the ED has long been problematic, especially with regard to the intensity of care for patients near the end of life. We sought to investigate the utility of MO consultation at the ED in indicating the best supportive care for cancer patients.
Methods
Consecutive MO consultations with patients presented to the ED from January 1 to March 31, 2024 were recorded. MO indication of best supportive care (BSC) was correlated with overall survival (OS) and 30-day mortality rate (30-DMR). Additionally, 47 clinical and laboratory candidate variables were collected and correlated with OS. Significant variables (p ≤0.005) selected at univariate analysis were analyzed in a multivariate Cox-regression model.
Results
Out of 10,896 adult ED visits, MO consultation was required in 120 visits (1.1% of cases) well below the 5% prevalence of cancer patient ED visits reported in the literature). The most common cancers for which consultation was required were lung, gastrointestinal, and genitourinary cancer, and most common presenting symptoms were pain (25%), dyspnea (25%), and neurological symptoms (19%). Following MO consultation, BSC was indicated in 47.8% of cases. BSC indication was associated to a significantly higher 30-DMR compared to active treatment indication: 25% vs 13%, HR 3.01 (95%CI: 1.34 to 6.71), p 0.007. Following univariate analysis, alkaline phosphatase (ALP), neutrophils-to-lymphocyte ratio, Charlson comorbidity index, concomitant infection and modified Glasgow prognostic score (mGPS) were selected for the multivariate model and ALP >100 IU/L (HR 5.28, 95%CI: 1.73-16.12, p 0.003) and mGPS score 2 (HR 12.78, 95%CI: 2.89-56.53, p 0.0008) were confirmed to be independent predictors of OS. Among patients eligible to active treatment, those with ALP>100 and/or mGPS=2 had a 30-DMR of 22% vs 6% of patients with ALP<100 and mGPS 0/1.
Conclusions
Early MO consultation is strongly recommended for the appropriate management of cancer patients in the Emergency Room. ALP and mGPS may assist prognostication in this setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1717TiP - CARE1 pragmatic clinical trial: First line randomised study platform to optimize treatment in patients with metastatic renal cell carcinoma
Presenter: Laurence Albiges
Session: Poster session 12
1822P - Incidence of cachexia and health resource use (HRU) in patients with breast, colorectal, lung, pancreatic, and prostate cancers
Presenter: Imran Ali
Session: Poster session 12
1823P - Significance of skeletal muscle measurement in cancer-associated cachexia screening
Presenter: Lynn Gottmann
Session: Poster session 12
1824P - Sarcopenia in advanced non-small cell lung cancer (NSCLC): Clinical impact and its biological correlates
Presenter: Filippo Dall'Olio
Session: Poster session 12
1826P - Risk factors and incidence of osteoporosis in patients with breast cancer according to gender
Presenter: Chang Ik Yoon
Session: Poster session 12
1827P - Bone health and body composition in prostate cancer: An italian consensus about prevention and management strategies
Presenter: Maria Concetta Cursano
Session: Poster session 12
1828P - A cross-sectional study investigating the current diagnostic & therapeutical approaches to bone metastases (BoM) in patients (pts) with non-small cell lung cancer (NSCLC)
Presenter: Sara Pilotto
Session: Poster session 12
1829P - Nutritional status assessment for patients with common cancer in a cancer hospital of southwest China
Presenter: Huiqing Yu
Session: Poster session 12
Resources:
Abstract
1830P - Comprehensive prognostic effects of inflammatory and nutritional markers to predict survival in women with breast cancer
Presenter: Susanna Hutajulu
Session: Poster session 12
1831P - Obesity and weight variations before treatment, seem to influence weight loss that happens during first-line metastatic lung adenocarcinoma
Presenter: Anthony Tarabay
Session: Poster session 12